- Report
- October 2023
- 157 Pages
Global
From €2977EUR$3,255USD£2,534GBP
€4253EUR$4,650USD£3,620GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €457EUR$500USD£389GBP
Pletal (cilostazol) is a cardiovascular drug used to treat intermittent claudication, a condition characterized by pain in the legs due to poor circulation. It works by increasing blood flow to the legs, allowing patients to walk further without pain. Pletal is a phosphodiesterase inhibitor, and is available in tablet form. It is typically prescribed in combination with lifestyle changes such as exercise and smoking cessation.
Pletal is used to treat a wide range of cardiovascular conditions, including peripheral artery disease, coronary artery disease, and stroke. It is also used to reduce the risk of recurrent stroke in patients with a history of stroke. Pletal is generally well-tolerated, with the most common side effects being headache, diarrhea, and nausea.
The Pletal market is highly competitive, with several major pharmaceutical companies offering the drug. These include Pfizer, Novartis, and Bayer. Other companies in the market include Mylan, Teva, and Sandoz. Show Less Read more